Back to Results
First PageMeta Content
Glioblastoma multiforme / O-6-methylguanine-DNA methyltransferase / European Organisation for Research and Treatment of Cancer / Oncology / Glioma / Brain tumor / Medicine / Temozolomide


Your Contact Phyllis Carter:
Add to Reading List

Document Date: 2014-01-22 11:38:16

Open Document

File Size: 34,79 KB

Share Result on Facebook

City

Lausanne / Darmstadt / /

Company

EMD Serono / Merck & Co. / Merck Serono / Merck KGaA / CENTRICa / 4 Merck KGaA / /

Continent

Europe / /

Country

Germany / Switzerland / United States / Canada / /

Currency

EUR / /

/

Event

FDA Phase / /

Facility

University Cancer Center / U.S. National Cancer Institute / University of Lausanne Medical Center / /

/

IndustryTerm

Treatment of Cancer / cancer care / cancer treatment / chemical / pharmaceutical / /

MedicalCondition

cancers / tumor / glioblastoma tumors / cancer / tumors / disease / multidisciplinary cancer / rare disease / nausea / media.relations@merckgroup.com News Release tumors / fatigue / nonsmall cell lung cancer / personalized cancer / glioblastoma Phase III / diagnOsed glioblastoma multifoRme / multicenter cancer / brain tumor / molecular tumor / Glioblastoma / /

MedicalTreatment

radiotherapy / surgery / anticancer therapies / /

Organization

European Organisation for Research and Treatment of Cancer / Department of Neurosurgery / Lausanne Medical Center / Zurich University Cancer Center / U.S. National Cancer Institute / American Society of Clinical Oncology / Treatment of Cancer / /

Person

Annalisa Jenkins / Phyllis Carter / /

/

Position

Professor / director / Head of Global Drug Development / www.merckgroup.com Head External Communications / lead investigator and president / Head / /

Product

Cilengitide Did Not / /

RadioStation

CORE / /

Technology

Neurosurgery / Drug Development / /

URL

www.merckgroup.com/subscribe / www.merckgroup.com / www.eortc.org / /

SocialTag